Fig. 8.

Inhibition of CK1δ/ε reduces PPARα and DEC1 expression. A: nuclear and cytosolic extracts were collected from AML12 cells treated with 10 μM casein kinase 1δ/ε inhibitor PF670462 for 72 h (CKinh). Western blot analysis was performed using anti-Per1 or anti-β-actin antibodies as a loading control. Data are representative of three independent experiments. B: densitometry analysis was used to quantitate the level of Per1 in (A); n = 3. AML12 cells were treated with 10 μM casein kinase 1δ/ε inhibitor PF670462 for 72 h. QPCR was used to evaluate changes in PPARα (C) and DEC1 (D) gene expression in PF670462-treated cells vs. DMSO-treated cells; n = 3. AML12 cells were treated with nontarget or casein kinase 1δ and ε siRNA for 48 h. Real-time PCR was used to evaluate changes in CK1δ (E), CK1ε (F), PPARα (G), or DEC1 (H) gene expression in casein kinase 1δ/ε siRNA-treated cells vs. nontarget. *P < 0.05, **P < 0.01, ***P < 0.001; n = 4. Values are means ± SE.